15.10

1.55% 0.23

After Hours: 15.10

Y Mabs Therapeutics Inc (YMAB)

Overview News Price History Option Chain Financials Discussions Forecast

Y Mabs Therapeutics Inc stock is traded at $15.10, with a volume of 266.22K. It is up +1.55% in the last 24 hours and up +6.64% over the past month. Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Previous Close:

$14.87

Open:

$14.77

24h Volume:

266.22K

Relative Volume:

1.08

Market Cap:

$673.00M

Revenue:

$84.82M

Net Income/Loss:

$-21.43M

P/E Ratio:

-16.97

EPS:

-0.89

Net Cash Flow:

$-27.23M

1W Performance:

+2.44%

1M Performance:

+6.64%

6M Performance:

-11.95%

1Y Performance:

+176.05%

1-Day Range:

$14.77

$15.22

1-Week Range:

$14.19

$15.22

52-Week Range:

$4.69

$20.90

Y Mabs Therapeutics Inc Stock (YMAB) Company Profile

Name

Y Mabs Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

212-847-9841

Address

230 PARK AVENUE, NEW YORK, NY

Employee

100

Twitter

Next Earnings Date

2024-11-08

Latest SEC Filings

YMAB's Discussions on Twitter

Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-16-24	Initiated	Cantor Fitzgerald	Overweight
Jun-28-24	Initiated	Truist	Buy
May-10-23	Upgrade	Wedbush	Neutral → Outperform
Apr-03-23	Downgrade	Guggenheim	Buy → Neutral
Jan-27-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jan-05-23	Downgrade	Cowen	Outperform → Market Perform
Dec-02-22	Downgrade	BofA Securities	Buy → Neutral
Oct-31-22	Downgrade	JP Morgan	Neutral → Underweight
Oct-31-22	Downgrade	Wedbush	Outperform → Neutral
Jul-06-22	Resumed	Canaccord Genuity	Buy
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Feb-03-22	Resumed	Guggenheim	Buy
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Nov-16-21	Downgrade	JP Morgan	Overweight → Neutral
May-07-21	Upgrade	BofA Securities	Neutral → Buy
Apr-23-21	Resumed	Cowen	Outperform
Mar-22-21	Resumed	JP Morgan	Overweight
Jan-15-21	Downgrade	BofA Securities	Buy → Neutral
Nov-09-20	Reiterated	H.C. Wainwright	Buy
May-05-20	Initiated	Barclays	Overweight
May-01-20	Initiated	Janney	Buy
Apr-29-20	Initiated	Morgan Stanley	Equal-Weight
Dec-24-19	Initiated	JP Morgan	Overweight
Nov-20-19	Initiated	Guggenheim	Buy
Sep-04-19	Initiated	Wedbush	Outperform
Apr-01-19	Initiated	H.C. Wainwright	Buy
Oct-16-18	Initiated	BTIG Research	Buy
Oct-16-18	Initiated	BofA/Merrill	Buy

View All

Y Mabs Therapeutics Inc Stock (YMAB) Latest News

09:06 AM

(YMAB) Trading Advice - Stock Traders Daily

09:06 AM

04:19 AM

Vanguard Group Inc's Strategic Acquisition in Y-mAbs Therapeutics Inc - GuruFocus.com

04:19 AM

12:49 PM

Y-mAbs enters Japan market with Nobelpharma for cancer therapy By Investing.com - Investing.com Canada

12:49 PM

Nov 04, 2024

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan - The Manila Times

Nov 04, 2024

Nov 02, 2024

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 02, 2024

Nov 01, 2024

Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know - MSN

Nov 01, 2024

Y-mAbs Therapeutics (YMAB) Scheduled to Post Quarterly Earnings on Friday - Defense World

Nov 01, 2024

Y-mAbs Therapeutics (YMAB) Scheduled to Post Earnings on Friday - MarketBeat

Nov 01, 2024

Oct 30, 2024

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Benzinga

Oct 30, 2024

Oct 29, 2024

Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal - Law360

Oct 29, 2024

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail

Oct 29, 2024

Oct 27, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Oct 27, 2024

Oct 25, 2024

Objective long/short (YMAB) Report - Stock Traders Daily

Oct 25, 2024

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast - The Manila Times

Oct 25, 2024